Bullish option flow detected in Medtronic (MDT) with 13,596 calls trading, 3x expected, and implied vol increasing over 1 point to 19.29%.
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
Hosted on MSN1d
FDA Takes Action on Allergies, Diabetes, Parkinson’s, and Deadly Food Safety Scare—What You Need to KnowThe U.S. Food and Drug Administration (FDA) has announced several significant developments this week, spanning advancements ...
Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas, ...
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback